{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAK-385&page=3",
    "query": {
      "intervention": "TAK-385",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAK-385&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAK-385&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T22:37:15.586Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06531499",
      "title": "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AAA617",
          "type": "DRUG"
        },
        {
          "name": "Gonadotropin-releasing hormone (GnRH) analogues",
          "type": "DRUG"
        },
        {
          "name": "Gonadotropin-releasing hormone (GnRH) antagonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 110,
      "start_date": "2024-11-11",
      "completion_date": "2029-04-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06531499"
    },
    {
      "nct_id": "NCT06397703",
      "title": "ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Leuprolide, Degarelix or Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic body radiation therapy/radiosurgery (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 392,
      "start_date": "2024-04-16",
      "completion_date": "2031-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06397703"
    },
    {
      "nct_id": "NCT05241860",
      "title": "Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Sensitive Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pharmacotherapy Discontinuation",
          "type": "OTHER"
        },
        {
          "name": "Follow-Up",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 79,
      "start_date": "2022-11-21",
      "completion_date": "2033-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 326,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241860"
    },
    {
      "nct_id": "NCT05765500",
      "title": "RecoverPC: Relugolix vs GnRH Agonist in Quality of Life",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 110,
      "start_date": "2024-02-12",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Foxborough, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Foxborough",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05765500"
    },
    {
      "nct_id": "NCT06111313",
      "title": "The University of Miami Adapt (UAdapt) Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "FTLEAD",
          "type": "RADIATION"
        },
        {
          "name": "Ultra-Short-Term Androgen Deprivation Therapy with Relugolix",
          "type": "DRUG"
        },
        {
          "name": "HypoLEAD",
          "type": "RADIATION"
        },
        {
          "name": "ADT Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "MALE",
        "summary": "35 Years to 85 Years · Male only"
      },
      "enrollment_count": 130,
      "start_date": "2024-11-06",
      "completion_date": "2033-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111313"
    },
    {
      "nct_id": "NCT05053152",
      "title": "Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oligometastatic Prostate Carcinoma",
        "Prostate Adenocarcinoma",
        "Prostate Ductal Adenocarcinoma",
        "Prostate Intraductal Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluciclovine F18",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "PSMA PET Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 194,
      "start_date": "2022-04-20",
      "completion_date": "2034-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 242,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053152"
    },
    {
      "nct_id": "NCT05467176",
      "title": "A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 999,
      "start_date": "2022-10-04",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 96,
      "location_summary": "Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05467176"
    },
    {
      "nct_id": "NCT05862272",
      "title": "A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Relugolix Combination Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2023-08-14",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 120,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05862272"
    },
    {
      "nct_id": "NCT05320406",
      "title": "RElugolix VErsus LeUprolide Cardiac Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Biochemically Recurrent Prostate Carcinoma",
        "Localized Prostate Carcinoma",
        "Stage I Prostate Cancer AJCC v8",
        "Stage II Prostate Cancer AJCC v8",
        "Stage IIA Prostate Cancer AJCC v8",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 94,
      "start_date": "2022-06-06",
      "completion_date": "2026-10-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05320406"
    },
    {
      "nct_id": "NCT07142551",
      "title": "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) analogue",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-09",
      "completion_date": "2034-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-16T22:37:15.586Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142551"
    }
  ]
}